



## **Anthem Biosciences LIMITED**

**Issue Opens - July 14, 2025 to July 16, 2025**

**Price Band**  
**₹540 to ₹570**

**Face Value**  
₹2

**Issue Size**  
₹3,395.00 Cr

**Lot Size**  
26 Shares

**Listing At**  
NSE, BSE

**Issue Size**

**5,95,61,404 shares / ₹3,395.00 Cr**

**Fresh Issue**

**No Fresh Issue**

**Offer for Sale**

**5,95,61,404 shares of ₹2 / ₹3,395.00 Cr**

**Retail Quota**

**Min. 35% of the Issue Size**

**Tentative Allotment**

**Thu, Jul 17, 2025**

**Initiation of Refunds**

**Fri, Jul 18, 2025**

**Credit of Shares to Demat**

**Fri, Jul 18, 2025**

**"Anthem Biosciences LTD" Listing  
Day**

**Mon, Jul 21, 2025**

# Objects of The Offer



The Company proposes to utilize the Net Proceeds towards funding the following objects :

- Anthem Biosciences limited expects the proposed listing of its Equity Shares to enhance its visibility and brand image, as well as provide liquidity to its Shareholders and create a public market for the Equity Shares in India
- Anthem Biosciences limited will not receive any proceeds from the Offer for Sale.

## Brief profile of the Directors

1. **Ajay Bhardwaj** is the Chairman, Managing Director and the Chief Executive Officer of the Company. He holds a Bachelor's degree in Chemical Engineering from the Indian Institute of Technology (Delhi) and a Master's degree of Science in Chemical Engineering from Louisiana State University and Agricultural and Mechanical College. He has over 40 years of experience in life sciences, contract research and pharmaceutical manufacturing.
2. **Ganesh Sambasivam** is a Whole-time Director and the Chief Scientific Officer of the Company. He holds a Bachelor's degree of Science in Chemistry from the University of Madras, a Master's degree in Organic Chemistry from the 244 University of Pune and a Ph.D. in Chemistry from the University of Pune. He was previously associated with Syngene International Limited as the Chief Scientific Officer. He has more than 31 years of experience in process R&D.
3. **K Ravindra Chandrappa** is a Whole-time Director and the Chief Operating Officer, of the Company. He holds a Bachelor's degree in Chemical Engineering from Bangalore University. He is responsible for leading the end-to-end operations including research and development, manufacturing, quality and regulatory compliance management. He has more than 25 years of experience in the field of pharmaceutical and biopharmaceutical industry along with experience in managing large scale operations, driving process efficiencies and implementing global quality standards.
4. **Satish Chander Subbanna** is a Non-Executive Nominee Director of the Company. He holds a Bachelor's Degree in Mechanical Engineering from the Indian Institute of Technology, Madras and a Post Graduate Diploma in Management from Indian Institute of Management, Calcutta. He has been associated with True North for over 19 years and leads True North's investments in healthcare and life sciences sectors
5. **Ramesh Ramadurai** is a Non-Executive Independent Director of the Company. He holds a Bachelor's degree of Technology in Chemical Engineering from Indian Institute of Technology, Kanpur and a Post Graduate Diploma in Management from Indian Institute of Management, Calcutta. He currently serves as the managing director of 3M India Limited and has over 35 years of experience in 3M India Limited.
6. **Ravikant Uppal** is a Non-Executive Independent Director of the Company. He holds a Bachelor's degree in Mechanical Engineering from Indian Institute of Technology, Delhi and a Post Graduate Diploma in Business Administration from Indian Institute of Management, Ahmedabad. Additionally, he is also a Graduate of The Wharton Advanced Management Programme from the University of Pennsylvania. He has over 23 years of experience in business administration.
7. **Subramanian Madhavan** is a Non-Executive Independent Director of the Company. He holds a Master's degree in Business Administration from the Indian Institute of Management, Ahmedabad. He is a qualified Fellow Chartered Accountant from the Institute of Chartered Accountants of India. He has over 11 years of experience in finance and taxation
8. **Shubha Kulkarni** is a Non-Executive Independent Woman Director of the Company. She holds a Bachelor's degree in Economics (Hons.) from Delhi University and a Master's degree in Human Resources from Jamia Millia Islamia, New Delhi, where she also received a gold medal. She has over 13 years of experience in the field of human resources.

# About The Company and Business Overview



- **Anthem Biosciences Limited** is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in India, offering integrated, end-to-end solutions across the pharmaceutical and biotech value chain. Incorporated in 2006 and operational since 2007, Anthem has evolved into a full-service platform that supports clients from early drug discovery through development to commercial manufacturing.
- **Integrated CRDMO Platform:** Anthem provides a comprehensive value chain that includes drug discovery, preclinical development, clinical trial material manufacturing, regulatory filing support, and commercial manufacturing of APIs, biologics, and formulations. This integration reduces fragmentation, compliance hurdles, and transfer costs for clients.
- **Core Business Segments:**
  - *Contract Research Services:* Includes target validation, medicinal chemistry, ADME profiling, preclinical safety studies, and GLP toxicology. Generated INR 200 crore in FY24 with 21% year-on-year growth.
  - *Development Services:* Encompasses process optimization, scale-up, formulation R&D, and analytical development, contributing INR 130 crore in FY24 and driving repeat business.
  - *Manufacturing Services:* Manufacturing of Active Pharmaceutical Ingredients (APIs), formulations, and biologics. APIs constitute about 40% of total revenue. Manufacturing revenue was INR 580 crore in FY24.
  - *Specialty Ingredients:* Production and sale of fermentation-based specialty ingredients such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars, targeting both regulated and semi-regulated markets globally.
  - *Licensing and Royalties:* Revenue from intellectual property co-developed with clients, contributing INR 35 crore in FY24 with potential for high-margin growth.



- **Revenue Model:** Anthem operates on a mix of fee-for-service (fixed and milestone-based), per-batch manufacturing pricing, and royalty-sharing agreements, providing predictable and scalable revenue streams.
- **Clientele and Markets:** Serves over 550 customers across 44+ countries, including mid- and large-cap pharmaceutical and biotech companies, with 65% revenue from regulated markets like the US and Europe. Repeat business rate exceeds 75%.
- **Technology and Infrastructure:** Anthem boasts world-class R&D labs, cGMP kilo labs, pilot plants, and manufacturing facilities in Bangalore, India. It employs over 1,500 scientists and engineers skilled in chemistry, biology, fermentation, and bioprocessing.
- **Regulatory Compliance and Quality:** Facilities have been inspected and approved by USFDA, PMDA (Japan), and EU Qualified Persons (QPs), ensuring adherence to global quality standards.

## Financial ratios

Financial Ratios	ROCE	ROE	PE	INDUSTRY PE	EV / EBITDA
Syngene International Ltd	13.15	10.50	53.30	43.50	22.40
Sai Life Sciences Ltd	13.19	10.90	94.50	33.60	37.90
Cohance Lifesciences Ltd	16.80	14.10	147.00	33.60	90.40
Divis Laboratories Ltd	20.40	15.40	83.30	33.60	53.80
<b>Anthem Biosciences Ltd</b>	<b>26.88</b>	<b>20.82</b>	<b>62.06 - 65.51</b>	<b>33.60</b>	<b>-</b>

# Strengths



- **Integrated End-to-End CRDMO Capabilities:** Anthem is one of the few Indian companies offering comprehensive, one-stop services across the drug lifecycle for both small molecules and biologics. This includes drug discovery, development, and commercial manufacturing, making it a preferred partner for global pharmaceutical and biotech clients.
- **Strong Customer Relationships and Retention:** The company serves a diverse global customer base, with over 287 customers across more than 3,000 projects in the last three years. Top clients have maintained relationships for an average of 12 years, reflecting high customer loyalty and trust.
- **Robust Financial Performance:** Anthem has demonstrated strong revenue and profit growth, with revenue rising nearly 30% year-on-year in FY25 and profit after tax reaching ₹451.26 crore. The company maintains healthy margins, with ROE at 20% and ROCE at 25%.
- **Scalable Manufacturing Infrastructure:** The company operates two cGMP-compliant manufacturing facilities with significant synthesis and fermentation capacity, and expansion plans are underway to further increase capacity.
- **Strategic Focus on High-Growth Segments:** Anthem targets the fast-growing segment of small pharma and emerging biotech companies, which are expected to outpace large pharma in growth over the next five years.
- **Regulatory Compliance and Quality:** Facilities are approved by major global regulators, including USFDA, PMDA (Japan), and EU QPs, supporting credibility in regulated markets.
- **Experienced Leadership and Talent Pool:** The company is led by experienced professionals and employs over 1,500 scientists and engineers, supporting innovation and operational excellence.

## Key Risk Factors

- **Revenue Concentration:** A significant portion of revenue is concentrated among a few customers: the top five clients contributed over 70% of revenue in FY25. Loss of any major client could materially impact financials.
- **Geographical Concentration:** The company derives over 80% of its revenue from North America and Europe, exposing it to regulatory, economic, and currency risks in these regions. Anthem does not hedge foreign currency receivables, increasing vulnerability to exchange rate fluctuations.
- **Dependence on Molecule Success Rates:** Financial performance is closely tied to the success of client molecules. Failures in late-stage development or withdrawal of commercialized molecules can lead to revenue volatility, as seen in past years.
- **Supplier Concentration and Geopolitical Risks:** There is high dependence on overseas suppliers, especially a single PRC-based supplier accounting for over a quarter of total material costs. This creates supply chain and geopolitical risks.
- **Limited Patent Portfolio and IP Risks:** Anthem has a limited number of granted patents and several pending applications, with some trademark objections and oppositions. This could impact its ability to protect proprietary technologies globally.
- **Manufacturing Revenue Concentration:** Over 70% of revenue is derived from developmental and commercial manufacturing. Delays or failures in early-phase projects or inability to scale commercially viable drugs can adversely affect revenues.

# Statement of Profit and Loss



## Anthem Biosciences Limited

(All amounts are in Indian Rupees millions, unless otherwise stated)

Particulars	For the year ended 31, March 2025	For the year ended 31, March 2024	For the year ended 31, March 2023
I. Revenue from Operations	18,445.53	14,193.70	10,569.24
II. Other Income	857.32	636.99	770.68
<b>III. Total Revenue (I + II)</b>	<b>19,302.85</b>	<b>14,830.69</b>	<b>11,339.93</b>
<b>IV. Expenses</b>			
Cost of Materials Consumed	8,306.17	6,407.86	3,482.89
Changes in WIP & FG Inventories	(867.05)	(412.35)	(90.12)
Employee Benefits Expense	2,604.94	1,829.27	1,532.37
Finance Costs	103.29	95.35	67.63
Depreciation & Amortization	893.71	818.24	636.96
Other Expenses	1,693.11	1,319.13	1,355.25
<b>Total Expenses (IV)</b>	<b>12,734.17</b>	<b>10,057.51</b>	<b>6,984.97</b>
V. Profit before Exceptional Items & Tax	6,568.68	4,773.18	4,354.95
VI. Exceptional Items	–	–	618.02
<b>VII. Profit Before Tax</b>	<b>6,568.68</b>	<b>4,773.18</b>	<b>4,972.98</b>
<b>VIII. Tax Expense</b>			
Current Tax	1,820.27	1,264.11	1,200.48
Deferred Tax	235.81	(164.03)	(79.36)
<b>Total Tax Expense</b>	<b>2,056.08</b>	<b>1,100.08</b>	<b>1,121.13</b>
<b>IX. Profit for the Year</b>	<b>4,512.59</b>	<b>3,673.10</b>	<b>3,851.85</b>
X. Other Comprehensive Income			
Remeasurements of DB Plans	(5.30)	(3.31)	(2.79)
Deferred Tax on Above	1.33	0.83	10.35
<b>XI. Total Comprehensive Income</b>	<b>4,508.63</b>	<b>3,670.62</b>	<b>3,859.41</b>
<b>XII. Earnings Per Share (?)</b>			
<b>Basic EPS</b>	<b>8.07</b>	<b>6.48</b>	<b>6.75</b>
<b>Diluted EPS</b>	<b>8.04</b>	<b>6.48</b>	<b>6.75</b>

# Valuation and Outlook



**Anthem Biosciences limited** IPO is expected to be priced between ₹540 to ₹570 per share. At this price, the company is valued at Price-to-Earnings (P/E) ratio of **70.63x** while the industry peers are trading on average of **81.06x**

Name of the Company	Total Revenue	Face Value	Closing Price / Offer Price	P/E Ratio	EV/ EBITDA	Operating EBITDA	EPS (Basic)	EPS (Diluted)	RoNW (%)	Net Asset Value
Anthem Biosciences Limited	18,445.53	2.00	-	-	-	6,837.80	8.07	8.04	20.82	43.10
Listed Peers										
Syngene International Limited	36,424.00	10.00	635.95	51.54	23.93	10,418.00	12.35	12.34	11.05	117.42
Sai Life Sciences Limited	16,945.70	1.00	793.70	92.18	39.95	4,056.61	8.83	8.61	10.96	102.12
Cohance Lifesciences Limited	11,975.80	1.00	1,016.70	97.29	68.44	3,752.00	10.52	10.45	13.61	72.31
Divi's Laboratories Limited	93,600.00	2.00	6,868.50	83.22	60.07	29,680.00	82.53	82.53	15.35	564.87

Anthem Biosciences Ltd. (ABL) stands out as a prominent global player in the innovation-led, technology-driven CRDMO space. With its strong positioning and leadership in a niche segment, ABL has consistently expanded its revenue base over the years. The spike in profitability for FY23 was largely due to exceptional income adjustments. While the company's operational performance reflects robust growth and market leadership, the IPO valuation appears on the higher side, suggesting a premium has been factored into its leadership and growth potential.

**"Call us on 8448899576"** to find out whether or not you should apply.

## **Disclaimer:**

**This Report is for the personal information of the authorised recipient(s) and is not for public distribution and should not be reproduced or redistributed to any other person or in any form without prior permission of Ganesh Stock. The information provided in the report is from publicly available data, which we believe, are reliable but does not taken as an indication or guarantee of future performance/ assurance of returns. The Report also includes analysis and views of their team. The Report is purely for information purposes and does not construe to be investment recommendation/advice or an offer or solicitation of an offer to buy/sell any securities. Investment in Securities Market is subject to Market Risk.**

**Accordingly, Ganesh Stock or any of its connected persons including its directors or subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained, views and opinions expressed in this publication.**

**Investors should not solely rely on the information contained in this Report and must make investment decisions based on their own investment objectives, judgment, risk profile and financial position. The recipients of this report may take professional advice before acting on this information.**